Review



uppsala 87 u87 malignant glioma cell line  (ATCC)


Bioz Verified Symbol ATCC is a verified supplier
Bioz Manufacturer Symbol ATCC manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 99

    Structured Review

    ATCC uppsala 87 u87 malignant glioma cell line
    Generation of CAR T cell workflow, assessment of CAR transduction, and quantification of on-target antigens on <t>U87.</t> A) Pictographic representation of timeline for CAR T cell culturing and functional assessment. B) Flow cytometric gating strategy of representative donor to quantify CAR transduction applicable to both IL-13 and TV-13 CAR transduced cells. C) Comparative CAR expression distinguished between CD4 and CD8 from a representative donor of Control T Cells (UTD), TV-13, and IL-13 CARs. D) Flow cytometric verification of IL13Rα1 and IL13Rα2 expression on U87 cells.
    Uppsala 87 U87 Malignant Glioma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 10908 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/uppsala 87 u87 malignant glioma cell line/product/ATCC
    Average 99 stars, based on 10908 article reviews
    uppsala 87 u87 malignant glioma cell line - by Bioz Stars, 2026-02
    99/100 stars

    Images

    1) Product Images from "Multimodal profiling of CAR T cells against glioblastoma using a microengineered 3D tumor-on-a-chip model"

    Article Title: Multimodal profiling of CAR T cells against glioblastoma using a microengineered 3D tumor-on-a-chip model

    Journal: Bioactive Materials

    doi: 10.1016/j.bioactmat.2026.01.003

    Generation of CAR T cell workflow, assessment of CAR transduction, and quantification of on-target antigens on U87. A) Pictographic representation of timeline for CAR T cell culturing and functional assessment. B) Flow cytometric gating strategy of representative donor to quantify CAR transduction applicable to both IL-13 and TV-13 CAR transduced cells. C) Comparative CAR expression distinguished between CD4 and CD8 from a representative donor of Control T Cells (UTD), TV-13, and IL-13 CARs. D) Flow cytometric verification of IL13Rα1 and IL13Rα2 expression on U87 cells.
    Figure Legend Snippet: Generation of CAR T cell workflow, assessment of CAR transduction, and quantification of on-target antigens on U87. A) Pictographic representation of timeline for CAR T cell culturing and functional assessment. B) Flow cytometric gating strategy of representative donor to quantify CAR transduction applicable to both IL-13 and TV-13 CAR transduced cells. C) Comparative CAR expression distinguished between CD4 and CD8 from a representative donor of Control T Cells (UTD), TV-13, and IL-13 CARs. D) Flow cytometric verification of IL13Rα1 and IL13Rα2 expression on U87 cells.

    Techniques Used: Transduction, Cell Culture, Functional Assay, Expressing, Control

    2D in vitro cytotoxic assessment of CARs polyfunctionality. A) Workflow for intracellular cytokine assay. Created with BioRender.com . B) Flow cytometric gating strategy of the representative donor to identify CAR + T cells from viable singlets. C) Comparative release of IL-2 and TNF-α by CAR + T cells from the representative donor between UTD, TV-13, and IL-13 CAR transduced cells. D ) Comparative release of IFN-γ from the representative between UTD, TV-13, and IL-13 CAR T cells. E ) Graphical display of perforin and granzyme B release ( n = 3 ). ∗ p < 0.05. F) Quantification of the amount of INF-γ released into bulk media across UTD, TV-13, and IL-13 ( n = 3 ). One-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. G) Lactate Dehydrogenase (LDH) based quantification rate of tumor lysis across different T cell treatment conditions ( n = 3 ). One-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. H) Simplified Presentation of Incredibly Complex Evaluations (SPICE) analysis showing the number of intracellular cytokines (TNF-α, IFN-γ, and IL-2) produced per T cell by TV-13 and IL-13 CAR T cells, in response to U87 target stimulation indicating their polyfunctionality. The purple quadrant denotes the percentage of T cells producing all three cytokines, green represents cells producing two cytokines, blue denotes cells producing one, and grey represents cells producing none. Comparable levels of polyfunctionality were observed between the TV-13 and IL-13 groups. Data collected from three biological replicates ( n = 3 ).
    Figure Legend Snippet: 2D in vitro cytotoxic assessment of CARs polyfunctionality. A) Workflow for intracellular cytokine assay. Created with BioRender.com . B) Flow cytometric gating strategy of the representative donor to identify CAR + T cells from viable singlets. C) Comparative release of IL-2 and TNF-α by CAR + T cells from the representative donor between UTD, TV-13, and IL-13 CAR transduced cells. D ) Comparative release of IFN-γ from the representative between UTD, TV-13, and IL-13 CAR T cells. E ) Graphical display of perforin and granzyme B release ( n = 3 ). ∗ p < 0.05. F) Quantification of the amount of INF-γ released into bulk media across UTD, TV-13, and IL-13 ( n = 3 ). One-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. G) Lactate Dehydrogenase (LDH) based quantification rate of tumor lysis across different T cell treatment conditions ( n = 3 ). One-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. H) Simplified Presentation of Incredibly Complex Evaluations (SPICE) analysis showing the number of intracellular cytokines (TNF-α, IFN-γ, and IL-2) produced per T cell by TV-13 and IL-13 CAR T cells, in response to U87 target stimulation indicating their polyfunctionality. The purple quadrant denotes the percentage of T cells producing all three cytokines, green represents cells producing two cytokines, blue denotes cells producing one, and grey represents cells producing none. Comparable levels of polyfunctionality were observed between the TV-13 and IL-13 groups. Data collected from three biological replicates ( n = 3 ).

    Techniques Used: In Vitro, Cytokine Assay, Lysis, Produced

    Formation of 3D self-assembled microvascular network (μVN) and its influence on U87 cells. A) Establishment of the μVN. (i) Schematic representation detailing the formation of the self-assembled μVN, and (ii) Representative phase contrast tile image of the device showing the progression of μVN formation on day 0 (left) and day 7 (right). B) Characterization of the μVN. (i) 10X tile image of vascular region stained for endothelial marker CD31 (green), junctional protein CD144 (red), and counterstained for nuclei with DAPI (blue) (scale bar: 200 μm), (ii) Phase contrast region of interest (ROI) image highlighting the vascular bundle formed within the vascular region (left), alongside 20X immunofluorescent image showing the expression of CD31(middle), and wrapping of pericytes (α-SMA) around the vascular bundle (right). Scale bars: 100 μm. C) orthogonal sectioning of established μVN confirming the open lumen formation (white arrowhead indicates the open lumen in the orthogonal view). Scale bar: 50 μm. D) Representative immunofluorescent and phase contrast overlap image after injection of 70 kDa fluorescent dextran dye captured at 30s, 1,2, and 4min. Scale bars: 100 μm. E) Line graph image of co-localization of pericytes with endothelial cells based on the scan line (white line) from figure Bii (right). F) Representative immunofluorescent image captured after perfusion of 2 μm fluorescent bead (red) through the CD31 (green) stained vascular bundle. Scale bar: 100 μm. G) Characterization of the μVN in the presence of tumor cells. (i) 10X tile image showing the intact μVN in the vascular (V) region and the migration of the tumor cells (U87-green) from the tumor (T) to the stroma (S) region. Yellow dashed trapezoids and hexagons mark the microposts of the 3D GOC. Scale bar: 200 μm, and (ii) Orthogonal sectioning of the vascular region confirming the maintenance of lumens post U87 injection (white arrowhead indicates the open lumen with white dashed box showing a zoomed-in lumen). Scale bar: 50 μm. Actin acquired with Alexa 647 and CD31 stained with Alexa 555 were pseudo colored in gray and magenta, respectively, for visualization. T, S, V represent the tumor, stroma, and vascular regions of the GOC system.
    Figure Legend Snippet: Formation of 3D self-assembled microvascular network (μVN) and its influence on U87 cells. A) Establishment of the μVN. (i) Schematic representation detailing the formation of the self-assembled μVN, and (ii) Representative phase contrast tile image of the device showing the progression of μVN formation on day 0 (left) and day 7 (right). B) Characterization of the μVN. (i) 10X tile image of vascular region stained for endothelial marker CD31 (green), junctional protein CD144 (red), and counterstained for nuclei with DAPI (blue) (scale bar: 200 μm), (ii) Phase contrast region of interest (ROI) image highlighting the vascular bundle formed within the vascular region (left), alongside 20X immunofluorescent image showing the expression of CD31(middle), and wrapping of pericytes (α-SMA) around the vascular bundle (right). Scale bars: 100 μm. C) orthogonal sectioning of established μVN confirming the open lumen formation (white arrowhead indicates the open lumen in the orthogonal view). Scale bar: 50 μm. D) Representative immunofluorescent and phase contrast overlap image after injection of 70 kDa fluorescent dextran dye captured at 30s, 1,2, and 4min. Scale bars: 100 μm. E) Line graph image of co-localization of pericytes with endothelial cells based on the scan line (white line) from figure Bii (right). F) Representative immunofluorescent image captured after perfusion of 2 μm fluorescent bead (red) through the CD31 (green) stained vascular bundle. Scale bar: 100 μm. G) Characterization of the μVN in the presence of tumor cells. (i) 10X tile image showing the intact μVN in the vascular (V) region and the migration of the tumor cells (U87-green) from the tumor (T) to the stroma (S) region. Yellow dashed trapezoids and hexagons mark the microposts of the 3D GOC. Scale bar: 200 μm, and (ii) Orthogonal sectioning of the vascular region confirming the maintenance of lumens post U87 injection (white arrowhead indicates the open lumen with white dashed box showing a zoomed-in lumen). Scale bar: 50 μm. Actin acquired with Alexa 647 and CD31 stained with Alexa 555 were pseudo colored in gray and magenta, respectively, for visualization. T, S, V represent the tumor, stroma, and vascular regions of the GOC system.

    Techniques Used: Staining, Marker, Expressing, Injection, Migration

    Evaluation of cytotoxic abilities of T cells against GBM cells within the GOC model. A) Microfluidic 3D invasion assay. (i) Schematic representation depicting the culture of tumor cells with T cells on day 0 (top) and day 3 (bottom), (ii) Representative phase contrast tile image overlapped with GFP (tumor cells) channel captured on day 0 to show the distribution of tumor and T cells across the experimental conditions (Scale bars: 200 μm), and (iii) Representative phase contrast tile image overlapped with GFP channel showing the migration of the U87 cells (green) from the tumor region to the stroma region across three different T cell populations. The densities of U87 are kept consistent across all conditions, and the density of T cells varies from 4 × 10 6 to 15 × 10 6 cells/mL. Images were captured 72 h after the interaction of cells within the GOC model (Scale bars: 200 μm). T-tumor, S-stroma, and V-vascular regions of GOC. B) Assessment of tumor cell migration in the presence of different T cells. (i) Quantification of migration distance from the 3D microfluidic model showing dose-dependent inhibition of U87 migration by the CAR T cells. Data were measured on Day 3 from three biological replicates ( n = 3 ) and represented as mean ± SD, T cell donors: DN26, DN28, and DN31, ∗ p < 0.05, ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis, and (ii) Comparison of migration distance of the U87 cells in the presence of different concentrations of the T cell population. Analysis performed on samples captured on Day 3 of migration ( n = 3 ) and represented as mean ± SD, T cell donors: DN26, DN28, and DN31, ∗ p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. C) xCELLigence-based real-time evaluation of T cell cytolytic capacity. (i) Time-course of the average cell index ( n = 3 donors ) for UTD, TV-13, and IL-13 CAR T cell groups under a 10:1 E: T condition over a 7-day co-culture, measured using the xCELLigence platform, (ii) Bar plot of xCELLigence data comparing averaged cell index values of tumor cells at Day 0 and Day 7 across UTD, TV-13, and IL-13 CAR T cell groups. Data represent mean ± SEM ( n = 3 donors ), ∗ p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗ ∗p < 0.0001, Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis, (iii) xCELLigence data from a representative donor (Donor 31) showing dose-dependent killing of U87 cells achieved by five doses of TV-13 CAR T cells, and (iv) IL-13 CAR T cells during a 7-day co-culture period.
    Figure Legend Snippet: Evaluation of cytotoxic abilities of T cells against GBM cells within the GOC model. A) Microfluidic 3D invasion assay. (i) Schematic representation depicting the culture of tumor cells with T cells on day 0 (top) and day 3 (bottom), (ii) Representative phase contrast tile image overlapped with GFP (tumor cells) channel captured on day 0 to show the distribution of tumor and T cells across the experimental conditions (Scale bars: 200 μm), and (iii) Representative phase contrast tile image overlapped with GFP channel showing the migration of the U87 cells (green) from the tumor region to the stroma region across three different T cell populations. The densities of U87 are kept consistent across all conditions, and the density of T cells varies from 4 × 10 6 to 15 × 10 6 cells/mL. Images were captured 72 h after the interaction of cells within the GOC model (Scale bars: 200 μm). T-tumor, S-stroma, and V-vascular regions of GOC. B) Assessment of tumor cell migration in the presence of different T cells. (i) Quantification of migration distance from the 3D microfluidic model showing dose-dependent inhibition of U87 migration by the CAR T cells. Data were measured on Day 3 from three biological replicates ( n = 3 ) and represented as mean ± SD, T cell donors: DN26, DN28, and DN31, ∗ p < 0.05, ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis, and (ii) Comparison of migration distance of the U87 cells in the presence of different concentrations of the T cell population. Analysis performed on samples captured on Day 3 of migration ( n = 3 ) and represented as mean ± SD, T cell donors: DN26, DN28, and DN31, ∗ p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. C) xCELLigence-based real-time evaluation of T cell cytolytic capacity. (i) Time-course of the average cell index ( n = 3 donors ) for UTD, TV-13, and IL-13 CAR T cell groups under a 10:1 E: T condition over a 7-day co-culture, measured using the xCELLigence platform, (ii) Bar plot of xCELLigence data comparing averaged cell index values of tumor cells at Day 0 and Day 7 across UTD, TV-13, and IL-13 CAR T cell groups. Data represent mean ± SEM ( n = 3 donors ), ∗ p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗ ∗p < 0.0001, Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis, (iii) xCELLigence data from a representative donor (Donor 31) showing dose-dependent killing of U87 cells achieved by five doses of TV-13 CAR T cells, and (iv) IL-13 CAR T cells during a 7-day co-culture period.

    Techniques Used: Invasion Assay, Migration, Inhibition, Comparison, Co-Culture Assay

    Assessment of migratory behavior and proliferative potential of GBM tumor cells in the presence of engineered T cells. A) Evaluation of changes in migratory behavior of tumor cells across UTD, TV-13, and IL-13 T cells based on cytoskeletal organization. (i) Representative tile image of the 3D GOC model stained for actin cytoskeleton (red) showing the tumor-stroma-vascular interface (left), zoomed-in view highlighting the chain migration of the tumor cells from the tumor to the stroma region (middle), 20X region of interest (ROI) showing the disruption in the migratory pattern of the tumor cells and the formation of immune synapse (IS) (right). The white dashed box represents the ROIs alongside an inset image (ROI1) that highlights the formation of multiple IS between the tumor (green) and T cell within the stroma interface. The white arrow shows the IS formation, and the white dashed arrow represents the line scan utilized for intensity profiling to confirm the reorganization of actin cytoskeleton at the tumor-T cell interface . Red- Actin, Green- U87 cells, and DAPI – Blue . Scale bars: 200 μm (left and middle), 50 μm (right). (ii) Quantification of the number of cells migrating in a chain from near and far regions across three different T cell conditions . Data are represented as mean ± SD measured from three biological replicates ( n = 3 ), T cell donors: DN26, DN28, and DN31, ∗∗∗ p < 0.001 , ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis, (iii) Quantification of the number of cells within a field of view (FOV) from two distinct areas, namely near and far regions, Data are represented as mean ± SD measured from three biological replicated ( n = 3 ), T cell donors: DN26, DN28, and DN31, ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. B) Immunofluorescent images of the devices stained for proliferation marker Ki-67. (i) Representative 20X ROI image showing the Ki-67 (red) expression on U87 cells (green) and (ii) Quantification of the number of Ki-67 positive cells across each condition through the proliferative index (Ki-67/Nuclei Ratio), Data are represented as mean ± SD measured from three biological replicates ( n = 3 ), T cell donors: DN26, DN28, and DN31, ∗∗ p < 0.01. One-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis.
    Figure Legend Snippet: Assessment of migratory behavior and proliferative potential of GBM tumor cells in the presence of engineered T cells. A) Evaluation of changes in migratory behavior of tumor cells across UTD, TV-13, and IL-13 T cells based on cytoskeletal organization. (i) Representative tile image of the 3D GOC model stained for actin cytoskeleton (red) showing the tumor-stroma-vascular interface (left), zoomed-in view highlighting the chain migration of the tumor cells from the tumor to the stroma region (middle), 20X region of interest (ROI) showing the disruption in the migratory pattern of the tumor cells and the formation of immune synapse (IS) (right). The white dashed box represents the ROIs alongside an inset image (ROI1) that highlights the formation of multiple IS between the tumor (green) and T cell within the stroma interface. The white arrow shows the IS formation, and the white dashed arrow represents the line scan utilized for intensity profiling to confirm the reorganization of actin cytoskeleton at the tumor-T cell interface . Red- Actin, Green- U87 cells, and DAPI – Blue . Scale bars: 200 μm (left and middle), 50 μm (right). (ii) Quantification of the number of cells migrating in a chain from near and far regions across three different T cell conditions . Data are represented as mean ± SD measured from three biological replicates ( n = 3 ), T cell donors: DN26, DN28, and DN31, ∗∗∗ p < 0.001 , ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis, (iii) Quantification of the number of cells within a field of view (FOV) from two distinct areas, namely near and far regions, Data are represented as mean ± SD measured from three biological replicated ( n = 3 ), T cell donors: DN26, DN28, and DN31, ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. B) Immunofluorescent images of the devices stained for proliferation marker Ki-67. (i) Representative 20X ROI image showing the Ki-67 (red) expression on U87 cells (green) and (ii) Quantification of the number of Ki-67 positive cells across each condition through the proliferative index (Ki-67/Nuclei Ratio), Data are represented as mean ± SD measured from three biological replicates ( n = 3 ), T cell donors: DN26, DN28, and DN31, ∗∗ p < 0.01. One-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis.

    Techniques Used: Staining, Migration, Disruption, Marker, Expressing



    Similar Products

    99
    ATCC uppsala 87 u87 malignant glioma cell line
    Generation of CAR T cell workflow, assessment of CAR transduction, and quantification of on-target antigens on <t>U87.</t> A) Pictographic representation of timeline for CAR T cell culturing and functional assessment. B) Flow cytometric gating strategy of representative donor to quantify CAR transduction applicable to both IL-13 and TV-13 CAR transduced cells. C) Comparative CAR expression distinguished between CD4 and CD8 from a representative donor of Control T Cells (UTD), TV-13, and IL-13 CARs. D) Flow cytometric verification of IL13Rα1 and IL13Rα2 expression on U87 cells.
    Uppsala 87 U87 Malignant Glioma Cell Line, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/uppsala 87 u87 malignant glioma cell line/product/ATCC
    Average 99 stars, based on 1 article reviews
    uppsala 87 u87 malignant glioma cell line - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC u87 mg cells
    Generation of CAR T cell workflow, assessment of CAR transduction, and quantification of on-target antigens on <t>U87.</t> A) Pictographic representation of timeline for CAR T cell culturing and functional assessment. B) Flow cytometric gating strategy of representative donor to quantify CAR transduction applicable to both IL-13 and TV-13 CAR transduced cells. C) Comparative CAR expression distinguished between CD4 and CD8 from a representative donor of Control T Cells (UTD), TV-13, and IL-13 CARs. D) Flow cytometric verification of IL13Rα1 and IL13Rα2 expression on U87 cells.
    U87 Mg Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/u87 mg cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    u87 mg cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC human gbm cell line u87 gbm
    Generation of CAR T cell workflow, assessment of CAR transduction, and quantification of on-target antigens on <t>U87.</t> A) Pictographic representation of timeline for CAR T cell culturing and functional assessment. B) Flow cytometric gating strategy of representative donor to quantify CAR transduction applicable to both IL-13 and TV-13 CAR transduced cells. C) Comparative CAR expression distinguished between CD4 and CD8 from a representative donor of Control T Cells (UTD), TV-13, and IL-13 CARs. D) Flow cytometric verification of IL13Rα1 and IL13Rα2 expression on U87 cells.
    Human Gbm Cell Line U87 Gbm, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human gbm cell line u87 gbm/product/ATCC
    Average 99 stars, based on 1 article reviews
    human gbm cell line u87 gbm - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC transcription 3 tem transmission electron microscopy tme tumor microenvironment tmz temozolomide u87 mg human glioblastoma cell line u87 mg
    Generation of CAR T cell workflow, assessment of CAR transduction, and quantification of on-target antigens on <t>U87.</t> A) Pictographic representation of timeline for CAR T cell culturing and functional assessment. B) Flow cytometric gating strategy of representative donor to quantify CAR transduction applicable to both IL-13 and TV-13 CAR transduced cells. C) Comparative CAR expression distinguished between CD4 and CD8 from a representative donor of Control T Cells (UTD), TV-13, and IL-13 CARs. D) Flow cytometric verification of IL13Rα1 and IL13Rα2 expression on U87 cells.
    Transcription 3 Tem Transmission Electron Microscopy Tme Tumor Microenvironment Tmz Temozolomide U87 Mg Human Glioblastoma Cell Line U87 Mg, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/transcription 3 tem transmission electron microscopy tme tumor microenvironment tmz temozolomide u87 mg human glioblastoma cell line u87 mg/product/ATCC
    Average 99 stars, based on 1 article reviews
    transcription 3 tem transmission electron microscopy tme tumor microenvironment tmz temozolomide u87 mg human glioblastoma cell line u87 mg - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC human glioblastoma cell lines u87 mg
    Generation of CAR T cell workflow, assessment of CAR transduction, and quantification of on-target antigens on <t>U87.</t> A) Pictographic representation of timeline for CAR T cell culturing and functional assessment. B) Flow cytometric gating strategy of representative donor to quantify CAR transduction applicable to both IL-13 and TV-13 CAR transduced cells. C) Comparative CAR expression distinguished between CD4 and CD8 from a representative donor of Control T Cells (UTD), TV-13, and IL-13 CARs. D) Flow cytometric verification of IL13Rα1 and IL13Rα2 expression on U87 cells.
    Human Glioblastoma Cell Lines U87 Mg, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human glioblastoma cell lines u87 mg/product/ATCC
    Average 99 stars, based on 1 article reviews
    human glioblastoma cell lines u87 mg - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC human gbm cell lines u87
    Overexpression of VMP1 promotes tumor growth. (A) Representative western blot image validating exogenous overexpression of VMP1 in <t>U87</t> and U251 cell lines. (B) U87 subcutaneous xenografts of overexpressed VMP1 (VMP1‐OE) and control vector at Day 17 post‐injection ( n = 9). (C) The weight of the tumor grafts. (D) Quantification of normalized tumor weights of VMP1‐OE and vector (measured every 4 days from Day 3) ( n = 9). (E) Bioluminescence imaging of U87 VMP1‐OE and vector orthotopic xenografts at different time points from Day 3 to Day 17 ( n = 6). (F) Representative images of hematoxylin and eosin‐stained sections at Day 17 post‐injection. Tumor is indicated within the dashed line. Scale bar, 1000 µm. (G) Relative total photon flux of bioluminescence in mice with U87 VMP1‐OE and vector. (H) Kaplan–Meier survival analysis of mice with U87 VMP1‐OE and vector intracranial xenografts ( n = 6). (I) Top, immunohistochemical staining showing Ki67‐positive cells in subcutaneous and intracranial xenografts. Scale bar, 100 µm. Bottom, quantification of Ki67‐positive cells (%) in subcutaneous and intracranial models. * p < 0.05; ** p < 0.01; *** p < 0.001.
    Human Gbm Cell Lines U87, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/human gbm cell lines u87/product/ATCC
    Average 99 stars, based on 1 article reviews
    human gbm cell lines u87 - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    99
    ATCC u87 glioblastoma cells
    Overexpression of VMP1 promotes tumor growth. (A) Representative western blot image validating exogenous overexpression of VMP1 in <t>U87</t> and U251 cell lines. (B) U87 subcutaneous xenografts of overexpressed VMP1 (VMP1‐OE) and control vector at Day 17 post‐injection ( n = 9). (C) The weight of the tumor grafts. (D) Quantification of normalized tumor weights of VMP1‐OE and vector (measured every 4 days from Day 3) ( n = 9). (E) Bioluminescence imaging of U87 VMP1‐OE and vector orthotopic xenografts at different time points from Day 3 to Day 17 ( n = 6). (F) Representative images of hematoxylin and eosin‐stained sections at Day 17 post‐injection. Tumor is indicated within the dashed line. Scale bar, 1000 µm. (G) Relative total photon flux of bioluminescence in mice with U87 VMP1‐OE and vector. (H) Kaplan–Meier survival analysis of mice with U87 VMP1‐OE and vector intracranial xenografts ( n = 6). (I) Top, immunohistochemical staining showing Ki67‐positive cells in subcutaneous and intracranial xenografts. Scale bar, 100 µm. Bottom, quantification of Ki67‐positive cells (%) in subcutaneous and intracranial models. * p < 0.05; ** p < 0.01; *** p < 0.001.
    U87 Glioblastoma Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/u87 glioblastoma cells/product/ATCC
    Average 99 stars, based on 1 article reviews
    u87 glioblastoma cells - by Bioz Stars, 2026-02
    99/100 stars
      Buy from Supplier

    Image Search Results


    Generation of CAR T cell workflow, assessment of CAR transduction, and quantification of on-target antigens on U87. A) Pictographic representation of timeline for CAR T cell culturing and functional assessment. B) Flow cytometric gating strategy of representative donor to quantify CAR transduction applicable to both IL-13 and TV-13 CAR transduced cells. C) Comparative CAR expression distinguished between CD4 and CD8 from a representative donor of Control T Cells (UTD), TV-13, and IL-13 CARs. D) Flow cytometric verification of IL13Rα1 and IL13Rα2 expression on U87 cells.

    Journal: Bioactive Materials

    Article Title: Multimodal profiling of CAR T cells against glioblastoma using a microengineered 3D tumor-on-a-chip model

    doi: 10.1016/j.bioactmat.2026.01.003

    Figure Lengend Snippet: Generation of CAR T cell workflow, assessment of CAR transduction, and quantification of on-target antigens on U87. A) Pictographic representation of timeline for CAR T cell culturing and functional assessment. B) Flow cytometric gating strategy of representative donor to quantify CAR transduction applicable to both IL-13 and TV-13 CAR transduced cells. C) Comparative CAR expression distinguished between CD4 and CD8 from a representative donor of Control T Cells (UTD), TV-13, and IL-13 CARs. D) Flow cytometric verification of IL13Rα1 and IL13Rα2 expression on U87 cells.

    Article Snippet: U87 Culture : The Uppsala 87 (U87) Malignant Glioma cell line (HTB-14, ATCC) performed as the target tumor for this study was cultured in complete media composed of Eagle's minimum essential medium (EMEM) with L-Glutamine, and supplemented with 10 % FBS, 1 % HEPES, and 1 % penicillin-streptomycin.

    Techniques: Transduction, Cell Culture, Functional Assay, Expressing, Control

    2D in vitro cytotoxic assessment of CARs polyfunctionality. A) Workflow for intracellular cytokine assay. Created with BioRender.com . B) Flow cytometric gating strategy of the representative donor to identify CAR + T cells from viable singlets. C) Comparative release of IL-2 and TNF-α by CAR + T cells from the representative donor between UTD, TV-13, and IL-13 CAR transduced cells. D ) Comparative release of IFN-γ from the representative between UTD, TV-13, and IL-13 CAR T cells. E ) Graphical display of perforin and granzyme B release ( n = 3 ). ∗ p < 0.05. F) Quantification of the amount of INF-γ released into bulk media across UTD, TV-13, and IL-13 ( n = 3 ). One-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. G) Lactate Dehydrogenase (LDH) based quantification rate of tumor lysis across different T cell treatment conditions ( n = 3 ). One-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. H) Simplified Presentation of Incredibly Complex Evaluations (SPICE) analysis showing the number of intracellular cytokines (TNF-α, IFN-γ, and IL-2) produced per T cell by TV-13 and IL-13 CAR T cells, in response to U87 target stimulation indicating their polyfunctionality. The purple quadrant denotes the percentage of T cells producing all three cytokines, green represents cells producing two cytokines, blue denotes cells producing one, and grey represents cells producing none. Comparable levels of polyfunctionality were observed between the TV-13 and IL-13 groups. Data collected from three biological replicates ( n = 3 ).

    Journal: Bioactive Materials

    Article Title: Multimodal profiling of CAR T cells against glioblastoma using a microengineered 3D tumor-on-a-chip model

    doi: 10.1016/j.bioactmat.2026.01.003

    Figure Lengend Snippet: 2D in vitro cytotoxic assessment of CARs polyfunctionality. A) Workflow for intracellular cytokine assay. Created with BioRender.com . B) Flow cytometric gating strategy of the representative donor to identify CAR + T cells from viable singlets. C) Comparative release of IL-2 and TNF-α by CAR + T cells from the representative donor between UTD, TV-13, and IL-13 CAR transduced cells. D ) Comparative release of IFN-γ from the representative between UTD, TV-13, and IL-13 CAR T cells. E ) Graphical display of perforin and granzyme B release ( n = 3 ). ∗ p < 0.05. F) Quantification of the amount of INF-γ released into bulk media across UTD, TV-13, and IL-13 ( n = 3 ). One-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. G) Lactate Dehydrogenase (LDH) based quantification rate of tumor lysis across different T cell treatment conditions ( n = 3 ). One-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. H) Simplified Presentation of Incredibly Complex Evaluations (SPICE) analysis showing the number of intracellular cytokines (TNF-α, IFN-γ, and IL-2) produced per T cell by TV-13 and IL-13 CAR T cells, in response to U87 target stimulation indicating their polyfunctionality. The purple quadrant denotes the percentage of T cells producing all three cytokines, green represents cells producing two cytokines, blue denotes cells producing one, and grey represents cells producing none. Comparable levels of polyfunctionality were observed between the TV-13 and IL-13 groups. Data collected from three biological replicates ( n = 3 ).

    Article Snippet: U87 Culture : The Uppsala 87 (U87) Malignant Glioma cell line (HTB-14, ATCC) performed as the target tumor for this study was cultured in complete media composed of Eagle's minimum essential medium (EMEM) with L-Glutamine, and supplemented with 10 % FBS, 1 % HEPES, and 1 % penicillin-streptomycin.

    Techniques: In Vitro, Cytokine Assay, Lysis, Produced

    Formation of 3D self-assembled microvascular network (μVN) and its influence on U87 cells. A) Establishment of the μVN. (i) Schematic representation detailing the formation of the self-assembled μVN, and (ii) Representative phase contrast tile image of the device showing the progression of μVN formation on day 0 (left) and day 7 (right). B) Characterization of the μVN. (i) 10X tile image of vascular region stained for endothelial marker CD31 (green), junctional protein CD144 (red), and counterstained for nuclei with DAPI (blue) (scale bar: 200 μm), (ii) Phase contrast region of interest (ROI) image highlighting the vascular bundle formed within the vascular region (left), alongside 20X immunofluorescent image showing the expression of CD31(middle), and wrapping of pericytes (α-SMA) around the vascular bundle (right). Scale bars: 100 μm. C) orthogonal sectioning of established μVN confirming the open lumen formation (white arrowhead indicates the open lumen in the orthogonal view). Scale bar: 50 μm. D) Representative immunofluorescent and phase contrast overlap image after injection of 70 kDa fluorescent dextran dye captured at 30s, 1,2, and 4min. Scale bars: 100 μm. E) Line graph image of co-localization of pericytes with endothelial cells based on the scan line (white line) from figure Bii (right). F) Representative immunofluorescent image captured after perfusion of 2 μm fluorescent bead (red) through the CD31 (green) stained vascular bundle. Scale bar: 100 μm. G) Characterization of the μVN in the presence of tumor cells. (i) 10X tile image showing the intact μVN in the vascular (V) region and the migration of the tumor cells (U87-green) from the tumor (T) to the stroma (S) region. Yellow dashed trapezoids and hexagons mark the microposts of the 3D GOC. Scale bar: 200 μm, and (ii) Orthogonal sectioning of the vascular region confirming the maintenance of lumens post U87 injection (white arrowhead indicates the open lumen with white dashed box showing a zoomed-in lumen). Scale bar: 50 μm. Actin acquired with Alexa 647 and CD31 stained with Alexa 555 were pseudo colored in gray and magenta, respectively, for visualization. T, S, V represent the tumor, stroma, and vascular regions of the GOC system.

    Journal: Bioactive Materials

    Article Title: Multimodal profiling of CAR T cells against glioblastoma using a microengineered 3D tumor-on-a-chip model

    doi: 10.1016/j.bioactmat.2026.01.003

    Figure Lengend Snippet: Formation of 3D self-assembled microvascular network (μVN) and its influence on U87 cells. A) Establishment of the μVN. (i) Schematic representation detailing the formation of the self-assembled μVN, and (ii) Representative phase contrast tile image of the device showing the progression of μVN formation on day 0 (left) and day 7 (right). B) Characterization of the μVN. (i) 10X tile image of vascular region stained for endothelial marker CD31 (green), junctional protein CD144 (red), and counterstained for nuclei with DAPI (blue) (scale bar: 200 μm), (ii) Phase contrast region of interest (ROI) image highlighting the vascular bundle formed within the vascular region (left), alongside 20X immunofluorescent image showing the expression of CD31(middle), and wrapping of pericytes (α-SMA) around the vascular bundle (right). Scale bars: 100 μm. C) orthogonal sectioning of established μVN confirming the open lumen formation (white arrowhead indicates the open lumen in the orthogonal view). Scale bar: 50 μm. D) Representative immunofluorescent and phase contrast overlap image after injection of 70 kDa fluorescent dextran dye captured at 30s, 1,2, and 4min. Scale bars: 100 μm. E) Line graph image of co-localization of pericytes with endothelial cells based on the scan line (white line) from figure Bii (right). F) Representative immunofluorescent image captured after perfusion of 2 μm fluorescent bead (red) through the CD31 (green) stained vascular bundle. Scale bar: 100 μm. G) Characterization of the μVN in the presence of tumor cells. (i) 10X tile image showing the intact μVN in the vascular (V) region and the migration of the tumor cells (U87-green) from the tumor (T) to the stroma (S) region. Yellow dashed trapezoids and hexagons mark the microposts of the 3D GOC. Scale bar: 200 μm, and (ii) Orthogonal sectioning of the vascular region confirming the maintenance of lumens post U87 injection (white arrowhead indicates the open lumen with white dashed box showing a zoomed-in lumen). Scale bar: 50 μm. Actin acquired with Alexa 647 and CD31 stained with Alexa 555 were pseudo colored in gray and magenta, respectively, for visualization. T, S, V represent the tumor, stroma, and vascular regions of the GOC system.

    Article Snippet: U87 Culture : The Uppsala 87 (U87) Malignant Glioma cell line (HTB-14, ATCC) performed as the target tumor for this study was cultured in complete media composed of Eagle's minimum essential medium (EMEM) with L-Glutamine, and supplemented with 10 % FBS, 1 % HEPES, and 1 % penicillin-streptomycin.

    Techniques: Staining, Marker, Expressing, Injection, Migration

    Evaluation of cytotoxic abilities of T cells against GBM cells within the GOC model. A) Microfluidic 3D invasion assay. (i) Schematic representation depicting the culture of tumor cells with T cells on day 0 (top) and day 3 (bottom), (ii) Representative phase contrast tile image overlapped with GFP (tumor cells) channel captured on day 0 to show the distribution of tumor and T cells across the experimental conditions (Scale bars: 200 μm), and (iii) Representative phase contrast tile image overlapped with GFP channel showing the migration of the U87 cells (green) from the tumor region to the stroma region across three different T cell populations. The densities of U87 are kept consistent across all conditions, and the density of T cells varies from 4 × 10 6 to 15 × 10 6 cells/mL. Images were captured 72 h after the interaction of cells within the GOC model (Scale bars: 200 μm). T-tumor, S-stroma, and V-vascular regions of GOC. B) Assessment of tumor cell migration in the presence of different T cells. (i) Quantification of migration distance from the 3D microfluidic model showing dose-dependent inhibition of U87 migration by the CAR T cells. Data were measured on Day 3 from three biological replicates ( n = 3 ) and represented as mean ± SD, T cell donors: DN26, DN28, and DN31, ∗ p < 0.05, ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis, and (ii) Comparison of migration distance of the U87 cells in the presence of different concentrations of the T cell population. Analysis performed on samples captured on Day 3 of migration ( n = 3 ) and represented as mean ± SD, T cell donors: DN26, DN28, and DN31, ∗ p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. C) xCELLigence-based real-time evaluation of T cell cytolytic capacity. (i) Time-course of the average cell index ( n = 3 donors ) for UTD, TV-13, and IL-13 CAR T cell groups under a 10:1 E: T condition over a 7-day co-culture, measured using the xCELLigence platform, (ii) Bar plot of xCELLigence data comparing averaged cell index values of tumor cells at Day 0 and Day 7 across UTD, TV-13, and IL-13 CAR T cell groups. Data represent mean ± SEM ( n = 3 donors ), ∗ p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗ ∗p < 0.0001, Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis, (iii) xCELLigence data from a representative donor (Donor 31) showing dose-dependent killing of U87 cells achieved by five doses of TV-13 CAR T cells, and (iv) IL-13 CAR T cells during a 7-day co-culture period.

    Journal: Bioactive Materials

    Article Title: Multimodal profiling of CAR T cells against glioblastoma using a microengineered 3D tumor-on-a-chip model

    doi: 10.1016/j.bioactmat.2026.01.003

    Figure Lengend Snippet: Evaluation of cytotoxic abilities of T cells against GBM cells within the GOC model. A) Microfluidic 3D invasion assay. (i) Schematic representation depicting the culture of tumor cells with T cells on day 0 (top) and day 3 (bottom), (ii) Representative phase contrast tile image overlapped with GFP (tumor cells) channel captured on day 0 to show the distribution of tumor and T cells across the experimental conditions (Scale bars: 200 μm), and (iii) Representative phase contrast tile image overlapped with GFP channel showing the migration of the U87 cells (green) from the tumor region to the stroma region across three different T cell populations. The densities of U87 are kept consistent across all conditions, and the density of T cells varies from 4 × 10 6 to 15 × 10 6 cells/mL. Images were captured 72 h after the interaction of cells within the GOC model (Scale bars: 200 μm). T-tumor, S-stroma, and V-vascular regions of GOC. B) Assessment of tumor cell migration in the presence of different T cells. (i) Quantification of migration distance from the 3D microfluidic model showing dose-dependent inhibition of U87 migration by the CAR T cells. Data were measured on Day 3 from three biological replicates ( n = 3 ) and represented as mean ± SD, T cell donors: DN26, DN28, and DN31, ∗ p < 0.05, ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis, and (ii) Comparison of migration distance of the U87 cells in the presence of different concentrations of the T cell population. Analysis performed on samples captured on Day 3 of migration ( n = 3 ) and represented as mean ± SD, T cell donors: DN26, DN28, and DN31, ∗ p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. C) xCELLigence-based real-time evaluation of T cell cytolytic capacity. (i) Time-course of the average cell index ( n = 3 donors ) for UTD, TV-13, and IL-13 CAR T cell groups under a 10:1 E: T condition over a 7-day co-culture, measured using the xCELLigence platform, (ii) Bar plot of xCELLigence data comparing averaged cell index values of tumor cells at Day 0 and Day 7 across UTD, TV-13, and IL-13 CAR T cell groups. Data represent mean ± SEM ( n = 3 donors ), ∗ p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001, ∗∗∗ ∗p < 0.0001, Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis, (iii) xCELLigence data from a representative donor (Donor 31) showing dose-dependent killing of U87 cells achieved by five doses of TV-13 CAR T cells, and (iv) IL-13 CAR T cells during a 7-day co-culture period.

    Article Snippet: U87 Culture : The Uppsala 87 (U87) Malignant Glioma cell line (HTB-14, ATCC) performed as the target tumor for this study was cultured in complete media composed of Eagle's minimum essential medium (EMEM) with L-Glutamine, and supplemented with 10 % FBS, 1 % HEPES, and 1 % penicillin-streptomycin.

    Techniques: Invasion Assay, Migration, Inhibition, Comparison, Co-Culture Assay

    Assessment of migratory behavior and proliferative potential of GBM tumor cells in the presence of engineered T cells. A) Evaluation of changes in migratory behavior of tumor cells across UTD, TV-13, and IL-13 T cells based on cytoskeletal organization. (i) Representative tile image of the 3D GOC model stained for actin cytoskeleton (red) showing the tumor-stroma-vascular interface (left), zoomed-in view highlighting the chain migration of the tumor cells from the tumor to the stroma region (middle), 20X region of interest (ROI) showing the disruption in the migratory pattern of the tumor cells and the formation of immune synapse (IS) (right). The white dashed box represents the ROIs alongside an inset image (ROI1) that highlights the formation of multiple IS between the tumor (green) and T cell within the stroma interface. The white arrow shows the IS formation, and the white dashed arrow represents the line scan utilized for intensity profiling to confirm the reorganization of actin cytoskeleton at the tumor-T cell interface . Red- Actin, Green- U87 cells, and DAPI – Blue . Scale bars: 200 μm (left and middle), 50 μm (right). (ii) Quantification of the number of cells migrating in a chain from near and far regions across three different T cell conditions . Data are represented as mean ± SD measured from three biological replicates ( n = 3 ), T cell donors: DN26, DN28, and DN31, ∗∗∗ p < 0.001 , ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis, (iii) Quantification of the number of cells within a field of view (FOV) from two distinct areas, namely near and far regions, Data are represented as mean ± SD measured from three biological replicated ( n = 3 ), T cell donors: DN26, DN28, and DN31, ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. B) Immunofluorescent images of the devices stained for proliferation marker Ki-67. (i) Representative 20X ROI image showing the Ki-67 (red) expression on U87 cells (green) and (ii) Quantification of the number of Ki-67 positive cells across each condition through the proliferative index (Ki-67/Nuclei Ratio), Data are represented as mean ± SD measured from three biological replicates ( n = 3 ), T cell donors: DN26, DN28, and DN31, ∗∗ p < 0.01. One-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis.

    Journal: Bioactive Materials

    Article Title: Multimodal profiling of CAR T cells against glioblastoma using a microengineered 3D tumor-on-a-chip model

    doi: 10.1016/j.bioactmat.2026.01.003

    Figure Lengend Snippet: Assessment of migratory behavior and proliferative potential of GBM tumor cells in the presence of engineered T cells. A) Evaluation of changes in migratory behavior of tumor cells across UTD, TV-13, and IL-13 T cells based on cytoskeletal organization. (i) Representative tile image of the 3D GOC model stained for actin cytoskeleton (red) showing the tumor-stroma-vascular interface (left), zoomed-in view highlighting the chain migration of the tumor cells from the tumor to the stroma region (middle), 20X region of interest (ROI) showing the disruption in the migratory pattern of the tumor cells and the formation of immune synapse (IS) (right). The white dashed box represents the ROIs alongside an inset image (ROI1) that highlights the formation of multiple IS between the tumor (green) and T cell within the stroma interface. The white arrow shows the IS formation, and the white dashed arrow represents the line scan utilized for intensity profiling to confirm the reorganization of actin cytoskeleton at the tumor-T cell interface . Red- Actin, Green- U87 cells, and DAPI – Blue . Scale bars: 200 μm (left and middle), 50 μm (right). (ii) Quantification of the number of cells migrating in a chain from near and far regions across three different T cell conditions . Data are represented as mean ± SD measured from three biological replicates ( n = 3 ), T cell donors: DN26, DN28, and DN31, ∗∗∗ p < 0.001 , ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis, (iii) Quantification of the number of cells within a field of view (FOV) from two distinct areas, namely near and far regions, Data are represented as mean ± SD measured from three biological replicated ( n = 3 ), T cell donors: DN26, DN28, and DN31, ∗∗∗ ∗p < 0.0001. Two-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis. B) Immunofluorescent images of the devices stained for proliferation marker Ki-67. (i) Representative 20X ROI image showing the Ki-67 (red) expression on U87 cells (green) and (ii) Quantification of the number of Ki-67 positive cells across each condition through the proliferative index (Ki-67/Nuclei Ratio), Data are represented as mean ± SD measured from three biological replicates ( n = 3 ), T cell donors: DN26, DN28, and DN31, ∗∗ p < 0.01. One-way ANOVA with Tukey's multiple comparisons test was utilized for statistical analysis.

    Article Snippet: U87 Culture : The Uppsala 87 (U87) Malignant Glioma cell line (HTB-14, ATCC) performed as the target tumor for this study was cultured in complete media composed of Eagle's minimum essential medium (EMEM) with L-Glutamine, and supplemented with 10 % FBS, 1 % HEPES, and 1 % penicillin-streptomycin.

    Techniques: Staining, Migration, Disruption, Marker, Expressing

    Overexpression of VMP1 promotes tumor growth. (A) Representative western blot image validating exogenous overexpression of VMP1 in U87 and U251 cell lines. (B) U87 subcutaneous xenografts of overexpressed VMP1 (VMP1‐OE) and control vector at Day 17 post‐injection ( n = 9). (C) The weight of the tumor grafts. (D) Quantification of normalized tumor weights of VMP1‐OE and vector (measured every 4 days from Day 3) ( n = 9). (E) Bioluminescence imaging of U87 VMP1‐OE and vector orthotopic xenografts at different time points from Day 3 to Day 17 ( n = 6). (F) Representative images of hematoxylin and eosin‐stained sections at Day 17 post‐injection. Tumor is indicated within the dashed line. Scale bar, 1000 µm. (G) Relative total photon flux of bioluminescence in mice with U87 VMP1‐OE and vector. (H) Kaplan–Meier survival analysis of mice with U87 VMP1‐OE and vector intracranial xenografts ( n = 6). (I) Top, immunohistochemical staining showing Ki67‐positive cells in subcutaneous and intracranial xenografts. Scale bar, 100 µm. Bottom, quantification of Ki67‐positive cells (%) in subcutaneous and intracranial models. * p < 0.05; ** p < 0.01; *** p < 0.001.

    Journal: MedComm

    Article Title: Integrative Single‐Cell Analysis Reveals Targetable Vacuole Membrane Protein 1‐Mediated Mechanism of Tumor Angiogenesis in Glioblastoma

    doi: 10.1002/mco2.70619

    Figure Lengend Snippet: Overexpression of VMP1 promotes tumor growth. (A) Representative western blot image validating exogenous overexpression of VMP1 in U87 and U251 cell lines. (B) U87 subcutaneous xenografts of overexpressed VMP1 (VMP1‐OE) and control vector at Day 17 post‐injection ( n = 9). (C) The weight of the tumor grafts. (D) Quantification of normalized tumor weights of VMP1‐OE and vector (measured every 4 days from Day 3) ( n = 9). (E) Bioluminescence imaging of U87 VMP1‐OE and vector orthotopic xenografts at different time points from Day 3 to Day 17 ( n = 6). (F) Representative images of hematoxylin and eosin‐stained sections at Day 17 post‐injection. Tumor is indicated within the dashed line. Scale bar, 1000 µm. (G) Relative total photon flux of bioluminescence in mice with U87 VMP1‐OE and vector. (H) Kaplan–Meier survival analysis of mice with U87 VMP1‐OE and vector intracranial xenografts ( n = 6). (I) Top, immunohistochemical staining showing Ki67‐positive cells in subcutaneous and intracranial xenografts. Scale bar, 100 µm. Bottom, quantification of Ki67‐positive cells (%) in subcutaneous and intracranial models. * p < 0.05; ** p < 0.01; *** p < 0.001.

    Article Snippet: Human embryonic kidney cells 293T (293T) and human GBM cell lines U87 and U251 were purchased from the American Type Culture Collection (ATCC).

    Techniques: Over Expression, Western Blot, Control, Plasmid Preparation, Injection, Imaging, Staining, Immunohistochemical staining

    VMP1 promoted tumor growth was independent of autophagy. (A) Representative western blot images of autophagy markers (p62 and LC3 I/II) in U87 and U251 cell lines with VMP1‐OE. (B) Representative transmission electron microscopy images of a cell in U87 and U251 with VMP1‐OE, showing no differences in autophagosome formation. Top: scale bar, 2 µm. Bottom: scale bar, 500 nm. (C) Western blot images of tissue samples from our glioma cohort (glioma) ( n = 47) and normal brain tissue (N), showing the protein expression of autophagy markers (p62, Beclin 1, and LC3 I/II). (D) Quantification of western blot images, patients were separated into two groups based on median VMP1 expression: VMP1 low glioma ( n = 23) and VMP1 high glioma ( n = 24). (E) Correlation analysis of western blot quantification value between VMP1 and autophagy markers (p62, Beclin 1, and LC3 I/II). (F) Confirmation of VMP1 knockdown in U87 and U251 cells using two different targeting sequences by western blot analysis. (G) U87 subcutaneous xenografts of VMP1 knockdown (shVMP1) and control vector (shNC) at Day 27 post‐injection ( n = 10) (left), and the tumor volume measured from Day 14 to Day 27 (right). (H) Bioluminescence imaging of U87 shVMP1 and vector orthotopic xenografts at Day 28. (I) Representative images of hematoxylin and eosin‐stained sections at Day 28 post‐injection. Scale bar, 2000 µm. (J) Kaplan–Meier survival analysis of mice with U87 shVMP1 and vector intracranial xenografts ( n = 5). (K) Representative western blot images of U87 shVMP1 and vector subcutaneous xenografts showing the expression of autophagy markers p62 and LC3 I/II (left). Quantification of band intensities normalized to GAPDH (right). ns, no statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001.

    Journal: MedComm

    Article Title: Integrative Single‐Cell Analysis Reveals Targetable Vacuole Membrane Protein 1‐Mediated Mechanism of Tumor Angiogenesis in Glioblastoma

    doi: 10.1002/mco2.70619

    Figure Lengend Snippet: VMP1 promoted tumor growth was independent of autophagy. (A) Representative western blot images of autophagy markers (p62 and LC3 I/II) in U87 and U251 cell lines with VMP1‐OE. (B) Representative transmission electron microscopy images of a cell in U87 and U251 with VMP1‐OE, showing no differences in autophagosome formation. Top: scale bar, 2 µm. Bottom: scale bar, 500 nm. (C) Western blot images of tissue samples from our glioma cohort (glioma) ( n = 47) and normal brain tissue (N), showing the protein expression of autophagy markers (p62, Beclin 1, and LC3 I/II). (D) Quantification of western blot images, patients were separated into two groups based on median VMP1 expression: VMP1 low glioma ( n = 23) and VMP1 high glioma ( n = 24). (E) Correlation analysis of western blot quantification value between VMP1 and autophagy markers (p62, Beclin 1, and LC3 I/II). (F) Confirmation of VMP1 knockdown in U87 and U251 cells using two different targeting sequences by western blot analysis. (G) U87 subcutaneous xenografts of VMP1 knockdown (shVMP1) and control vector (shNC) at Day 27 post‐injection ( n = 10) (left), and the tumor volume measured from Day 14 to Day 27 (right). (H) Bioluminescence imaging of U87 shVMP1 and vector orthotopic xenografts at Day 28. (I) Representative images of hematoxylin and eosin‐stained sections at Day 28 post‐injection. Scale bar, 2000 µm. (J) Kaplan–Meier survival analysis of mice with U87 shVMP1 and vector intracranial xenografts ( n = 5). (K) Representative western blot images of U87 shVMP1 and vector subcutaneous xenografts showing the expression of autophagy markers p62 and LC3 I/II (left). Quantification of band intensities normalized to GAPDH (right). ns, no statistical significance; * p < 0.05; ** p < 0.01; *** p < 0.001.

    Article Snippet: Human embryonic kidney cells 293T (293T) and human GBM cell lines U87 and U251 were purchased from the American Type Culture Collection (ATCC).

    Techniques: Western Blot, Transmission Assay, Electron Microscopy, Expressing, Knockdown, Control, Plasmid Preparation, Injection, Imaging, Staining

    VMP1 mediates angiogenesis and vascular permeability through activation of endothelial cells in the TME. (A) Representative western blot image (top) and quantification (bottom) of VEGFR2 expression in human primary endothelial cells (HUVEC) after culturing with conditioned medium (CM) collected from VMP1‐overexpressing glioblastoma cell lines U87 and U251. (B) Representative immunofluorescence image of VEGFR2 expression (red) and DAPI (blue) in HUVEC cultured with conditioned medium. Scale bar, 200 µm. (C) Representative immunofluorescence staining image of VE‐cadherin expression (red) and DAPI (blue) in HUVEC with CM. Scale bar, 200 µm. (D) Human protein angiogenesis array showing 55 angiogenesis‐related proteins in the CM collected. (E) Quantification of eight of the angiogenesis‐related proteins, including tissue factor (TF), granulocyte‐macrophage colony stimulating factor (GM‐CSF), macrophage inflammatory protein 1α (MIP1α), Serpin E1, Thrombospondin‐1 (THBS1), Angiogenin, tissue inhibitor of metalloproteinase 1 (TIMP‐1), and VEGF‐C. (F) Spatial distribution of spot degree between VMP1 high cancer cells and endothelial cells in the spatial mRNA dataset. (G–I) Spatial distribution of angiogenesis (G), Serpin E1 (H), and TIMP1 (I) expression in the spatial mRNA dataset. * p < 0.05; ** p < 0.01; *** p <0 .001.

    Journal: MedComm

    Article Title: Integrative Single‐Cell Analysis Reveals Targetable Vacuole Membrane Protein 1‐Mediated Mechanism of Tumor Angiogenesis in Glioblastoma

    doi: 10.1002/mco2.70619

    Figure Lengend Snippet: VMP1 mediates angiogenesis and vascular permeability through activation of endothelial cells in the TME. (A) Representative western blot image (top) and quantification (bottom) of VEGFR2 expression in human primary endothelial cells (HUVEC) after culturing with conditioned medium (CM) collected from VMP1‐overexpressing glioblastoma cell lines U87 and U251. (B) Representative immunofluorescence image of VEGFR2 expression (red) and DAPI (blue) in HUVEC cultured with conditioned medium. Scale bar, 200 µm. (C) Representative immunofluorescence staining image of VE‐cadherin expression (red) and DAPI (blue) in HUVEC with CM. Scale bar, 200 µm. (D) Human protein angiogenesis array showing 55 angiogenesis‐related proteins in the CM collected. (E) Quantification of eight of the angiogenesis‐related proteins, including tissue factor (TF), granulocyte‐macrophage colony stimulating factor (GM‐CSF), macrophage inflammatory protein 1α (MIP1α), Serpin E1, Thrombospondin‐1 (THBS1), Angiogenin, tissue inhibitor of metalloproteinase 1 (TIMP‐1), and VEGF‐C. (F) Spatial distribution of spot degree between VMP1 high cancer cells and endothelial cells in the spatial mRNA dataset. (G–I) Spatial distribution of angiogenesis (G), Serpin E1 (H), and TIMP1 (I) expression in the spatial mRNA dataset. * p < 0.05; ** p < 0.01; *** p <0 .001.

    Article Snippet: Human embryonic kidney cells 293T (293T) and human GBM cell lines U87 and U251 were purchased from the American Type Culture Collection (ATCC).

    Techniques: Permeability, Activation Assay, Western Blot, Expressing, Immunofluorescence, Cell Culture, Staining

    Targeted inhibition of VEGFA represses VMP1‐mediated tumor growth. (A) The treatment timeline and bioluminescence detection of mice treated with bevacizumab (BEV) at different time points (Day 3, Day 7, and Day 13). (B) Bioluminescence detection of U87 tumor‐bearing mice treated with BEV and vehicle. (C) Hematoxylin and eosin staining of mice brain, dotted area indicates the tumor region. Scale bar, 1000 µm. (D) Relative total photon flux in orthotopic mice model after treatment. (E) Changes in body weight in mice after treatments. (F) Kaplan–Meier survival of mice after being treated with bevacizumab and vector control. ns, no statistical significance.

    Journal: MedComm

    Article Title: Integrative Single‐Cell Analysis Reveals Targetable Vacuole Membrane Protein 1‐Mediated Mechanism of Tumor Angiogenesis in Glioblastoma

    doi: 10.1002/mco2.70619

    Figure Lengend Snippet: Targeted inhibition of VEGFA represses VMP1‐mediated tumor growth. (A) The treatment timeline and bioluminescence detection of mice treated with bevacizumab (BEV) at different time points (Day 3, Day 7, and Day 13). (B) Bioluminescence detection of U87 tumor‐bearing mice treated with BEV and vehicle. (C) Hematoxylin and eosin staining of mice brain, dotted area indicates the tumor region. Scale bar, 1000 µm. (D) Relative total photon flux in orthotopic mice model after treatment. (E) Changes in body weight in mice after treatments. (F) Kaplan–Meier survival of mice after being treated with bevacizumab and vector control. ns, no statistical significance.

    Article Snippet: Human embryonic kidney cells 293T (293T) and human GBM cell lines U87 and U251 were purchased from the American Type Culture Collection (ATCC).

    Techniques: Inhibition, Staining, Plasmid Preparation, Control